Ophthalmology coordination
Topical ophthalmic solutions with tidy handling profiles and tightly-timed courses — we run to the date of the next ophthalmology visit.
Ophthalmology coordination has grown substantially with recent approvals of the first targeted therapies for dry eye disease with meibomian gland dysfunction, Demodex blepharitis, presbyopia, and a number of retinal conditions. Most of the therapies are topical ophthalmic solutions dispensed as multidose bottles or single-unit ampoules; a smaller share are intraocular implants or injectables.
Ophthalmic therapies we commonly coordinate
- Dry eye disease — Miebo (perfluorohexyloctane, reduces tear evaporation in MGD) and Tryptyr (TRPM8 agonist, stimulates basal tear production).
- Demodex blepharitis — Xdemvy (lotilaner ophthalmic 0.25%, 6-week twice-daily course).
- Presbyopia — Vizz (aceclidine 1.44% pinhole-effect drop).
- Retinal disease — anti-complement and anti-VEGF biologics (coordinated with the treating retina specialist for injection-clinic delivery).
Why ophthalmic coordination is operationally tidy
Most ophthalmic solutions are room-temperature stable, single-patient use, and low on cold-chain demand. The coordination priority tends to be timing: a patient who is starting a 6-week course under the treating ophthalmologist's care wants the product in hand before the first scheduled review. We run to that date.